Program
Ticagrelor
Also written as “ticagrelor”, “AZD6140” and “Ticagrelor Tablets”.
Its studies are mostly in Acute Coronary Syndrome · Coronary Artery Disease · Anemia, Sickle Cell · Vaso-Occlusive Crises · Ischemic Attack, Transient, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 410 open or running | phase 4since Apr 19, 2011 | Oct 23, 2006 | none ahead |
| Boehringer Ingelheim | 20 open or running | phase 1since May 9, 2012 | May 9, 2012 | none ahead |
| Johnson & Johnson | 10 open or running | phase 2since Nov 13, 2014 | Nov 13, 2014 | none ahead |
Also a collaborator on its studies: parexel, iqvia-pty-ltd and Bayer.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 29 studies since Oct 23, 2006.
- Jan 14, 2014Phase 4 study in Non-ST Elevation Acute Coronary SyndromeAstraZeneca · NCT02052635 · 34 enrolled · United States
- Feb 12, 2014Phase 4 study in Stable Coronary Heart Disease (CHD)AstraZeneca · NCT02064985 · 61 enrolled · China
- Apr 22, 2014Phase 4 study in Peripheral Arterial DiseaseAstraZeneca · NCT02121288
- Aug 8, 20142 phase 2 studiesAstraZeneca · NCT02214121, NCT02227368
- Nov 13, 2014Johnson & Johnson's first study: phase 2 study in Acute Coronary SyndromeNew to Johnson & JohnsonJohnson & Johnson · NCT02293395 · 3,037 enrolled · United States, Argentina, Australia and more
- Mar 19, 2015Phase 4 study in Non-ST Elevated Myocardial InfarctionAstraZeneca · NCT02406248 · 108 enrolled · Taiwan
- Jun 17, 2015Phase 2 study in Anemia, Sickle CellAstraZeneca · NCT02482298 · 87 enrolled · United States, Egypt, France and more
- Apr 20, 2017Phase 1 study in Anemia, Sickle CellAstraZeneca · NCT03126695 · 44 enrolled · Germany
- Nov 20, 2017Phase 3 study in Ischemic Attack, TransientAstraZeneca · NCT03354429 · 11,016 enrolled · Argentina, Australia, Belgium and more
- Mar 16, 2018Phase 1 study in Anemia, Sickle CellAstraZeneca · NCT03492931 · 21 enrolled · Belgium, Italy, Kenya and more
- Jun 22, 2018Phase 3 study in Anemia, Sickle CellAstraZeneca · NCT03615924 · 193 enrolled · United States, Belgium, Brazil and more
- Feb 4, 2020Phase 3 study in Anemia, Sickle CellAstraZeneca · NCT04293172
- Oct 9, 2020Phase 1 study in Cardiovascular DiseasesAstraZeneca · NCT04588727 · 103 enrolled · United States
- Aug 2, 2024Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06554821 · 28 enrolled · Germany
TargetBeta
“Purinergic receptor P2Y12 negative allosteric modulator”ChEMBL 37, by rule
Other programs on P2RY12
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Clopidogrelrule | Sanofi | phase 4 | 71 |
| selatogrelrule | Viatris | phase 3 | 11 |
Studies
All 44 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06554821Healthy Participants · Germany | 1 | Completed | AstraZeneca | Oct 8, 2024 | 28 |
| NCT04588727Cardiovascular Diseases · United States | 1 | Completed | AstraZeneca | Jan 19, 2022 | 103 |
| NCT04293172Anemia, Sickle Cell | 3 | Withdrawn | AstraZeneca | Oct 10, 2022 | 0 |
| NCT03615924Anemia, Sickle Cell · United States, Belgium, Brazil and more | 3 | Terminated | AstraZeneca | Aug 13, 2020 | 193 |
| NCT03492931Anemia, Sickle Cell · Belgium, Italy, Kenya and more | 1 | Completed | AstraZeneca | May 7, 2019 | 21 |
| NCT03354429Ischemic Attack, Transient · Argentina, Australia, Belgium and more | 3 | Completed | AstraZeneca | Dec 13, 2019 | 11,016 |
| NCT03126695Anemia, Sickle Cell · Germany | 1 | Completed | AstraZeneca | Jul 24, 2017 | 44 |
| NCT02482298Anemia, Sickle Cell · United States, Egypt, France and more | 2 | Completed | AstraZeneca | Nov 16, 2016 | 87 |
| NCT02406248Non-ST Elevated Myocardial Infarction · Taiwan | 4 | Completed | AstraZeneca | Feb 9, 2017 | 108 |
| NCT02293395Acute Coronary Syndrome · United States, Argentina, Australia and more | 2 | Completed | Johnson & Johnson | Oct 14, 2016 | 3,037 |
| NCT02227368Peripheral Arterial Disease · United States | 2 | Terminated | AstraZeneca | May 23, 2016 | 40 |
| NCT02214121Anemia, Sickle Cell · United States, Canada, Kenya and more | 2 | Completed | AstraZeneca | Feb 27, 2017 | 46 |
| NCT02121288Peripheral Arterial Disease | 4 | Withdrawn | AstraZeneca | Feb 2016 | 0 |
| NCT02064985Stable Coronary Heart Disease (CHD) · China | 4 | Completed | AstraZeneca | Nov 2014 | 61 |
| NCT02052635Non-ST Elevation Acute Coronary Syndrome · United States | 4 | Terminated | AstraZeneca | Apr 2015 | 34 |
| NCT02022748Kidney Failure, Chronic · United States | 1 | Completed | AstraZeneca | May 9, 2016 | 27 |
| NCT01994720Ischemic Attack, Transient · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Mar 2, 2016 | 13,307 |
| NCT01991795Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Jan 25, 2019 | 19,271 |
| NCT01887626Bioavailability Heathy Volunteers · United Kingdom | 1 | Completed | AstraZeneca | Sep 2013 | 36 |
| NCT01870921Acute Coronary Syndrome · China | 4 | Completed | AstraZeneca | Sep 30, 2015 | 2,004 |
| NCT01864005Non-ST or ST Elevation Acute Coronary Syndromes · China | 4 | Completed | AstraZeneca | Mar 2014 | 60 |
| NCT01757262Coronary Disease | 3 | Withdrawn | AstraZeneca | Apr 2013 | 0 |
| NCT01744288Inhibition on Platelet Aggregation · United States | 1 | Completed | AstraZeneca | Apr 2014 | 258 |
| NCT01732822Peripheral Arterial Disease · United States, Argentina, Brazil and more | 3 | Completed | AstraZeneca | Sep 26, 2016 | 13,885 |
| NCT01734772Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jun 2013 | 48 |
| NCT01603082Acute Coronary Syndrome · United States | 4 | Completed | AstraZeneca | Jun 2014 | 343 |
| NCT01595854Healthy · Germany | 1 | Completed | Boehringer Ingelheim | Jun 2012 | 36 |
| NCT01588626Healthy · Japan | 1 | Completed | AstraZeneca | Jun 2012 | 12 |
| NCT01523392Stable Coronary Artery Disease · United States | 4 | Completed | AstraZeneca | Sep 2013 | 50 |
| NCT01523366Stable Coronary Artery Disease · United States | 4 | Completed | AstraZeneca | May 2013 | 53 |
| NCT01504906Healthy · United States | 1 | Completed | AstraZeneca | Jun 2012 | 20 |
| NCT01350921Drug Drug Interaction · United States, Sweden | 1 | Completed | AstraZeneca | Mar 2012 | 22 |
| NCT01347580Myocardial Infarction · Algeria, Australia, Austria and more | 4 | Completed | AstraZeneca | Nov 2013 | 1,875 |
| NCT01294462Acute Coronary Syndrome · Japan, Korea, Republic of, Taiwan | 3 | Completed | AstraZeneca | Jul 2012 | 801 |
| NCT01226602Blood Flow Speed · Sweden | 1 | Completed | AstraZeneca | Apr 2011 | 39 |
| NCT01225562Myocardial Infarction · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Dec 2014 | 21,379 |
| NCT01118325Stable Coronary Artery Disease · Japan, Philippines | 2 | Completed | AstraZeneca | Mar 2011 | 146 |
| NCT00738842Gout | 1 | Completed | AstraZeneca | Jul 2008 | 24 |
| NCT00733265Renal Insufficiency · United States | 1 | Completed | AstraZeneca | Sep 2008 | 24 |
| NCT00721448Pharmacokinetics · China | 1 | Completed | AstraZeneca | Aug 2008 | 24 |
| NCT00685906Healthy · United States | 1 | Completed | AstraZeneca | Oct 2008 | 24 |
| NCT00642811Coronary Artery Disease · United States, Canada, Denmark and more | 2 | Completed | AstraZeneca | Mar 2009 | 98 |
| NCT00528411Coronary Artery Disease · United States, United Kingdom | 2 | Completed | AstraZeneca | Mar 2009 | 123 |
| NCT00391872Acute Coronary Syndrome · United States, Argentina, Australia and more | 3 | Completed | AstraZeneca | Mar 2009 | 18,624 |
How it is read
Names in the registry
- “Ticagrelor”, 24 entries
- “ticagrelor”, 10 entries
- “AZD6140”, 7 entries
- “Ticagrelor Tablets”, 3 entries
- “Ticagrelor 60 mg”, 2 entries
Conditions, from the studies’ own filings
- Acute Coronary Syndrome, 7 studies
- Coronary Artery Disease, 5 studies
- Anemia, Sickle Cell, 4 studies
- Vaso-Occlusive Crises, 2 studies
- Ischemic Attack, Transient, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.